[Federal Register Volume 77, Number 209 (Monday, October 29, 2012)]
[Notices]
[Pages 65578-65579]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-26510]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Docket No. 2919]


Certain Hydroxyprogesterone Caproate and Products Containing the 
Same; Notice of Receipt of Complaint; Solicitation of Comments Relating 
to the Public Interest

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has received a complaint entitled Certain 
Hydroxyprogesterone Caproate and Products Containing the Same, DN 2919; 
the Commission is soliciting comments on any public interest issues 
raised by the complaint or complainant's filing under section 210.8(b) 
of the Commission's Rules of Practice and Procedure (19 CFR 210.8(b)).

FOR FURTHER INFORMATION CONTACT: Lisa R. Barton, Acting Secretary to 
the Commission, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, telephone (202) 205-2000. The public version of 
the complaint can be accessed on the Commission's electronic docket 
(EDIS) at http://edis.usitc.gov, and will be available for inspection 
during official business hours (8:45 a.m. to 5:15 p.m.) in the Office 
of the Secretary, U.S. International Trade Commission, 500 E Street 
SW., Washington, DC 20436, telephone (202) 205-2000.
    General information concerning the Commission may also be obtained 
by accessing its Internet server (http://www.usitc.gov). The public 
record for this investigation may be viewed on the Commission's 
electronic docket (EDIS) at http://edis.usitc.gov. Hearing-impaired 
persons are advised that information on this matter can be obtained by 
contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission has received a complaint and 
a submission pursuant to section 210.8(b) of the Commission's Rules of 
Practice and Procedure filed on behalf of K-V Pharmaceutical Company on 
October 23, 2012. The complaint alleges violations of section 337 of 
the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the 
United States, the sale for importation, and the sale within the United 
States after importation of certain hydroxyprogesterone caproate and 
products containing the same. The complaint names as respondents New 
England Compounding Pharmacy, Inc. of MA; Alwan Pharmacy & Compounding 
Center of IL; Avella Specialty Pharmacy of AZ; Bellevue Pharmacy of MO; 
Betapharma (Shanghai) Co., Ltd. of China; Boudreaux's Specialty 
Compounding of LA; California Pharmacy & Compounding Center of CA; 
College Pharmacy of CO; Compound Care Pharmacy of KY; Compounding 
Solutions of AL; Daniel Drug of TX; Five-Star Compounding Pharmacy of 
IA; Fagron, Inc. of MN; Hawthorne Pharmacy of SC; Health Dimensions 
Compounding Pharmacy of MI; Hopewell Pharmacy & Compounding Center of 
NJ; Hubei Gedian Humanwell Pharmaceutical Co., Ltd. of China; Hubei 
Saibo Chemical Co., Ltd. of China; Jinan Haohua Industry Co., Ltd. of 
China; Kelley-Ross & Associates, Inc. of WA; Lacey Drug Company/
Marietta Medical Center of GA; Letco Medical of AL; Medisca, Inc. of 
NV; Owens Healthcare Compounding Pharmacy of CA; Partners In Care, Inc. 
of GA; People's Custom Rx of TN; Pharmerica Corporation of KY; 
Prescription Compounds of LA; Rye Beach Pharmacy of NY; Sherry's Drug 
Compounding and Natural Pharmacy of OK; Shanghai Jinhong 
Biopharmaceutical, Ltd. of China; Stark Pharmacy of KS; The Compounder 
Pharmacy of IL; The Compounding Shoppe of AL; The Medicine Shoppe 
Pharmacy of IL; Triangle Compounding Pharmacy of NC; Trinity Healthcare 
Medical Center of FL; Universal Arts Pharmacy of FL; Village 
Compounding of TX; Wedgewood Pharmacy of NJ; Westmoreland Pharmacy & 
Compounding of IN; Williams Bros. Healthcare Pharmacy of IN; Wilson 
Pharmacy, Inc. of TN; Women's International Pharmacy of WI; Wuhan 
Xianghe Pharmaceutical, Co., Ltd. of China; and Xianju Hongyan 
Pharmaceutical Chemicals Co., Ltd. of China.
    Proposed respondents, other interested parties, and members of the 
public are invited to file comments, not to exceed five (5) pages in 
length, inclusive of attachments, on any public interest issues raised 
by the complaint or section 210.8(b) filing. Comments should address 
whether issuance of the relief specifically requested by the 
complainant in this investigation would affect the public health and 
welfare in the United States, competitive conditions in the United 
States economy, the production of like or directly competitive articles 
in the United States, or United States consumers.
    In particular, the Commission is interested in comments that:
    (i) Explain how the articles potentially subject to the requested 
remedial orders are used in the United States;
    (ii) Identify any public health, safety, or welfare concerns in the 
United States relating to the requested remedial orders;
    (iii) Identify like or directly competitive articles that 
complainant, its licensees, or third parties make in the United States 
which could replace the subject articles if they were to be excluded;
    (iv) Indicate whether complainant, complainant's licensees, and/or 
third party suppliers have the capacity to replace the volume of 
articles potentially subject to the requested exclusion order and/or a 
cease and desist order within a commercially reasonable time; and
    (v) Explain how the requested remedial orders would impact United 
States consumers.
    Written submissions must be filed no later than by close of 
business, eight calendar days after the date of publication of this 
notice in the Federal Register. There will be further opportunities for 
comment on the public interest after the issuance of any final initial 
determination in this investigation.
    Persons filing written submissions must file the original document 
electronically on or before the deadlines stated above and submit 8 
true paper copies to the Office of the Secretary by noon the next day 
pursuant to section 210.4(f) of the Commission's Rules of Practice and 
Procedure (19 CFR 210.4(f)). Submissions should refer to the docket 
number (``Docket No. 2919'') in a prominent place on the cover page 
and/or the first page. (See Handbook for Electronic Filing Procedures, 
http://www.usitc.gov/secretary/fed_reg_notices/rules/handbook_on_electronic_filing.pdf). Persons with questions regarding filing should 
contact the Secretary (202-205-2000).
    Any person desiring to submit a document to the Commission in 
confidence must request confidential treatment. All such requests 
should be directed to the Secretary to the Commission and must include 
a full statement of the reasons why the Commission should grant such

[[Page 65579]]

treatment. See 19 CFR 201.6. Documents for which confidential treatment 
by the Commission is properly sought will be treated accordingly. All 
nonconfidential written submissions will be available for public 
inspection at the Office of the Secretary and on EDIS.
    This action is taken under the authority of section 337 of the 
Tariff Act of 1930, as amended (19 U.S.C. 1337), and of sections 201.10 
and 210.8(c) of the Commission's Rules of Practice and Procedure (19 
CFR 201.10, 210.8(c)).

    By order of the Commission.

    Issued: October 24, 2012.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2012-26510 Filed 10-26-12; 8:45 am]
BILLING CODE 7020-02-P